ERCC1 and colorectal carcinoma: In addition, patients with stage III CRC with positive ERCC1 tumors also showed a statistically significant improvement in DFS (67%) and OS (71%), compared to patients with negative ERCC1 tumors (DFS 56%; HR: 1.45, 95% CI: 0.91–2.29, P = 0.03 and OS 57%; HR: 1.58, 95% CI: 0.9–2.52, P = 0.04).